Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Purdue's Abuse-Deterrent Oxycodone: Can Patients Stomach IR Product's Risks?

This article was originally published in The Pink Sheet Daily

Executive Summary

In a twist, opioid's major safety issue doesn't appear to be dependency, but food effects; FDA advisory committee to consider whether directions that Avridi be taken on an empty stomach are feasible given the immediate-release product's frequent dosing.



Related Companies